UNSPSC 51162726: Guaietolin

This classification denotes an expectorant with the molecular formula C11H16O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G9J54386JH, chemically known as 1,2-propanediol, 3-(o-ethoxyphenoxy)- but more generally known as guaietolin, which bears US NIH Compound Identifier 68825. European Medicines Agency schedules Guaietolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07972MIG.

UNSPSC 51162726 Guaietolin is a Commodity code representing pharmaceutical and health-system products that state and local governments procure for community health, emergency response, and public health programs. Recent solicitations under this code show state and local buyers acquiring naloxone (opioid antagonist), drug deactivation systems, and generic multi-source pharmaceuticals distributed through authorized wholesalers to support public health initiatives and facility operations. Issuing bodies include county health departments and state cooperative purchasing alliances administering contracts across multiple member jurisdictions. The work involves sourcing finished pharmaceutical products from manufacturers, managing supply-chain relationships with authorized distributors, meeting FDA compliance and Good Manufacturing Practice standards, and delivering products on defined schedules to end-use facilities.

Seminole County, Florida posted an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with responses due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with vendor proposals due March 26, 2026, and awarded products to become available July 1, 2026. Awarded vendors must maintain contractual relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, comply with the Drug Supply Chain Security Act, and accept a 3 percent administrative fee on all contract purchases with performance penalties ranging from $200 to $1,500 per violation.